Running Oak Capital LLC Sells 8,331 Shares of IQVIA Holdings Inc. $IQV

Running Oak Capital LLC trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 8.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 90,746 shares of the medical research company’s stock after selling 8,331 shares during the period. IQVIA makes up about 1.9% of Running Oak Capital LLC’s investment portfolio, making the stock its 15th largest holding. Running Oak Capital LLC owned 0.05% of IQVIA worth $17,236,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Atlantic Union Bankshares Corp bought a new stake in IQVIA in the 3rd quarter worth about $36,000. Bridges Investment Management Inc. boosted its holdings in shares of IQVIA by 2.2% during the 3rd quarter. Bridges Investment Management Inc. now owns 9,185 shares of the medical research company’s stock valued at $1,745,000 after acquiring an additional 198 shares during the last quarter. Jones Financial Companies Lllp grew its stake in shares of IQVIA by 56.4% in the third quarter. Jones Financial Companies Lllp now owns 6,115 shares of the medical research company’s stock worth $1,098,000 after acquiring an additional 2,204 shares during the period. Access Investment Management LLC purchased a new position in shares of IQVIA during the third quarter valued at approximately $401,000. Finally, FDx Advisors Inc. bought a new position in IQVIA during the third quarter valued at approximately $229,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

NYSE:IQV opened at $231.50 on Tuesday. The stock has a 50-day moving average price of $231.00 and a 200 day moving average price of $209.37. The stock has a market capitalization of $39.42 billion, a P/E ratio of 31.76, a P/E/G ratio of 2.34 and a beta of 1.36. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03.

Analysts Set New Price Targets

IQV has been the subject of a number of research reports. HSBC upgraded shares of IQVIA from a “hold” rating to a “buy” rating and boosted their target price for the company from $195.00 to $235.00 in a research note on Thursday, October 9th. Robert W. Baird set a $258.00 price objective on IQVIA and gave the company an “outperform” rating in a research report on Wednesday, October 29th. JPMorgan Chase & Co. raised their target price on IQVIA from $177.00 to $255.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 29th. TD Cowen upped their price objective on IQVIA from $215.00 to $245.00 and gave the stock a “hold” rating in a research note on Thursday, January 22nd. Finally, Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research report on Sunday, January 25th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $251.06.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.